Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 46.98 support.
  • The company returns high margins, thereby supporting business profitability.
  • Historically, the company has been releasing figures that are above expectations.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 42.51 USD
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • With an expected P/E ratio at 41.65 and 23.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Analysts covering the stock have recently lowered their earnings forecast.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
QIAGEN N.V.40.36%10 888
LONZA GROUP AG57.19%45 022
IQVIA HOLDINGS INC.-0.34%29 650
SEAGEN INC.45.98%29 023
CELLTRION, INC.33.15%28 374
MODERNA, INC.244.94%26 623
IMMUNOMEDICS, INC.315.22%20 324
INCYTE CORPORATION-0.78%18 948
HANGZHOU TIGERMED CONSULTIN..96.36%15 866
ALNYLAM PHARMACEUTICALS, IN..6.77%14 261
PHARMARON BEIJING CO., LTD.123.13%13 286
PPD, INC.0.00%11 497
CHARLES RIVER LABORATORIES ..49.06%11 373
BIO-TECHNE CORPORATION14.99%9 732
ICON PUBLIC LIMITED COMPANY4.65%9 512
GALAPAGOS NV-45.63%7 721
More Results
Financials (USD)
Sales 2020 1 814 M - -
Net income 2020 274 M - -
Net Debt 2020 996 M - -
P/E ratio 2020 41,7x
Yield 2020 -
Capitalization 10 888 M 10 888 M -
EV / Sales 2020 6,55x
EV / Sales 2021 5,64x
Nbr of Employees 5 300
Free-Float 92,9%
Upcoming event on QIAGEN N.V.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes